Beverly Tchang, an obesity medicine specialist at Weill Cornell Medicine, noted in the guideline committee's commentary: "Tirzepatide's dual GIP and GLP-1 receptor agonism produces weight reduction that rivals bariatric surgery outcomes in some patients, making insurance exclusions increasingly difficult to justify on clinical grounds" [11]
Semaglutide is FDA-approved for weight management and has been extensively studied for both safety and effectiveness
[DOI] [PubMed] [Google Scholar] 25.Wei X, Cui C, Fan C, Wu T, Li Y, Zhang X, Wang K, Pang Y, Yao P, Yang J
Semaglutide (brand names Ozempic, Wegovy, Rybelsus) and Tirzepatide (brand names Mounjaro, Zepbound) are injectable medications that help regulate blood sugar and reduce appetite by mimicking certain hormones involved in glucose regulation and digestion
Small, consistent changes are easier to maintain than drastic, short-lived ones